Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma

International Journal of Hyperthermia

Volumn 26, Issue 4, 2010, Pages 305-315

  Kim, Hye Ryun ^a,c   Ha Cheon, Seong ^a   Lee, Kwang Hun ^c   Ryun Ahn, Jung ^a,c   Jeung, Hei Cheul ^a,b,c   Sook Lee, Sung ^a,c   Cheol Chung, Hyun ^a,b,c   Hoon Noh, Sung ^a,c   Young Rha, Sun ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Gastric cancer; Liver metastases; Radiofrequency ablation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FEVER; GASTRECTOMY; HUMAN; HUMAN TISSUE; LIVER ABSCESS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SEPSIS; STOMACH ADENOCARCINOMA; SURGICAL INFECTION; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; CATHETER ABLATION; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77952471110     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656730903555696     Document Type: Article

References (54)

1. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008;19:1146-1153.
2. Marrelli D, Roviello F, De Stefano A, Fotia G, Giliberto C, Garosi L, Pinto E. Risk factors for liver metastases after curative surgical procedures for gastric cancer: A prospective study of 208 patients treated with surgical resection. J Am Coll Surg 2004;198:51-58.
3. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, Usuki H, Maeta H. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002;235:86-91.
4. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T, Makuuchi M. Surgical resection of liver metastases of gastric cancer: An analysis of a 17-year experience with 22 patients. Surgery 2003;133:507-511.
5. Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T, Sasako M. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007;95:534-539.
6. Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Mühlbacher F, Jakesz R, Längle F. Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg 2002;6:682-689.
7. Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, Yamaguchi T. Liver resection for metastatic gastric cancer: Experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol 2007;37:836-842.
8. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-221.
9. Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist 2008;13:794-806.
10. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909.
11. Yonemura Y, Matuki N, Sakuma H, Katayama K, Sawa T, Fujimura T, Ohyama S, Miwa K, Miyazaki I, Tanaka M, et al. Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases. Surg Today 1992;22:253-259.
12. Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, Roviello F, de Manzoni G, Nitti D, Giulini SM. Metachronous hepatic metastases from gastric carcinoma: A multicentric survey. Eur J Surg Oncol 2009;35:486-491.
13. Kumada T, Arai Y, Itoh K, Takayasu Y, Nakamura K, Ariyoshi Y, Tajima K. Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology 1999;57:216-223.
14. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-59.
15. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
16. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-2657.
17. Yonemura Y, Ohyama S, Kamata T, Fujimura T, Kimura H, Matsuki N, Sakuma H, Sawa T, Katayama K, Hasegawa H, et al. Multivariate analysis of gastric cancer patients with liver metastases. Gan To Kagaku Ryoho 1990;17:2063-2069.
18. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10:49-58.
19. Kang GH, Kim GS, Lee HR, Yuh YJ, Kim SR. A Phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer. Cancer Res Treat 2008;40:106-110.
20. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK. Solitary colorectal liver metastasis: Resection determines outcome. Arch Surg 2006;141:460-466, discussion 466-467.
21. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
22. Kornprat P, Jarnagin WR, DeMatteo RP, Fong Y, Blumgart LH, D'Angelica M. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg 2007;142:1087-1092.
23. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003;90:1240-1243. (Pubitemid 37330428)
24. Garrean Sean, JH, Saied Abdul, Helton WS, Espat NJ. Radiofreqency ablation of primary and metastatic liver tumors: A critical review of the literature. Am J Surg 2008;195:508-520.
25. Bremers AJ, Ruers TJ. Prudent application of radiofrequency ablation in resectable colorectal liver metastasis. Eur J Surg Oncol 2007;33:752-756.
26. Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007;33:67-71.
27. Rhim H. Review of Asian experience of thermal ablation techniques and clinical practice. Int J Hyperthermia 2004;20:699-712.
28. Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A, Kobayashi A, Kitamura H, Ikegami T, Miyagawa SI, Kawasaki S. A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol 2001;96:3178-3184.
29. Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Nakajima N. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001;181:279-283.
30. Bines SD, England G, Deziel DJ, Witt TR, Doolas A, Roseman DL. Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery 1993;114:799-805, discussion 804-795.
31. Miyazaki M, Itoh H, Nakagawa K, Ambiru S, Shimizu H, Togawa A, Shiobara M, Ohtsuka M, Sasada K, Shimizu Y, et al. Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol 1997;92:490-493.
32. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, Plaud B, Ducreux M, Spielmann M, Theodore C, Bonvalot S, Lasser P. Resection of liver metastases from a noncolorectal primary: Indications and results based on 147 monocentric patients. J Am Coll Surg 1998;187:487-493.
33. Foster JH. Survival after liver resection for secondary tumors. Am J Surg 1978;135:389-394.
34. Harrison LE, Brennan MF, NewmanE, Fortner JG, Picardo A, Blumgart LH, Fong Y. Hepatic resection for noncolorectal, nonneuroendocrine metastases: A fifteen-year experience with ninety-six patients. Surgery 1997;121:625-632.
35. An JY, Kim JY, Choi MG, Noh JH, Choi D, Sohn TS, Kim S. Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J 2008;49:1046-1051.
36. Kosaka T, Imaizumi H, Kamei K, Usami K, Nakano Y, Ueno K, Takashima S. A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy. Gan To Kagaku Ryoho 2004;31:1737-1739.
37. Carditello A, Scisca C, Stilo F, Parisi A, Basile M. The possible role of radiofrequency as complementary treatment of locally advanced gastric cancer. Annali italiani di chirurgia 2005;76:39-41.
38. AJCC Cancer Staging Manual. 6th edn. New York, NY: Springer, 2002, pp. 99-106.
39. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd III GD, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee Jr FT, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009;20:S377-390.
40. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
41. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003;14:S199-202.
42. Fumoleau P. Treatment of patients with liver metastases. Anticancer Drugs 1996;7:S21-23.
43. Frezza EE, Wachtel MS, Barragan B, Chiriva-Internati M, Cobos E. The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: A pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A 2007;17:282-284.
44. Schildberg FW, Meyer G, Piltz S, Koebe HG. Surgical treatment of tumor metastases: General considerations and results. Surg Today 1995;25:1-10.
45. Ribeiro Jr MA, Rodrigues JJ, Habr-Gama A, Chaib E, D'Ipolitto G, Fonseca AZ, Saad Jr WA, Saad WA. Radiofrequency ablation of primary and metastatic liver tumors - 4 years experience. Hepatogastroenterology 2007;54:1170-1175.
46. Mertyna P, Dewhirst MW, Halpern E, Goldberg W, Goldberg SN. Radiofrequency ablation: The effect of distance and baseline temperature on thermal dose required for coagulation. Int J Hyperthermia 2008;24:550-559.
47. Sorensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: Long-term survival. Acta Radiol 2007;48:253-258.
48. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007;246:559-565, discussion 565-557.
49. Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T. Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial? Ann Surg Oncol 2008;15:144-157.
50. Leen E, Horgan PG. Radiofrequency ablation of colorectal liver metastases. Surg Oncol 2007;16:47-51. (Pubitemid 46880338)
51. Rasmussen F. Radiofrequency ablation of liver metastases improves the survival rate of patients with metastatic colorectal disease. Acta Radiol 2007;48:250-251.
52. Pereira PL. Actual role of radiofrequency ablation of liver metastases. Eur Radiol 2007;17:2062-2070.
53. Nomura T, Kamio Y, Takasu N, Moriya T, Takeshita A, Mizutani M, Hachiya O, Hirai I, Kimura W. Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreat Surg 2009;16:493-501.
54. Shirabe K, Wakiyama S, Gion T, Watanabe M, Miyazaki M, Yoshinaga K, Tokunaga M, Nagaie T. Hepatic resection for the treatment of liver metastases in gastric carcinoma: Review of the literature. HPB (Oxford) 2006;8:89-92.